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Abstract
Enterococci are commensal bacteria in the intestines of humans and animals, but also cause infections in humans. Most often, Enterococ-
cus faecium isolates from clinical outbreaks belong to different types than E. faecium from animals, food, and humans in the community.
The same variants of the vanA gene cluster (Tn1546) encoding vancomycin resistance can be detected in enterococci of both human
and animal origin. This could indicate horizontal transfer of Tn1546 between enterococci of different origin. E. faecium isolates of animal
origin might not constitute a human hazard in themselves, but they could act as donors of antimicrobial resistance genes for other path-
ogenic enterococci. Enterococcus faecalis of animal origin seems to be a human hazard, as the same types can be detected in E. faecalis
from animals, meat, faecal samples from humans in the community, and patients with bloodstream infections.
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Introduction
Enterococci are commensal bacteria in the intestines of
humans and domestic animals, but they can also be detected
in the environment, from soil, water, plants, wild animals,
birds, and insects. In humans, Enterococcus faecalis and
Enterococcus faecium can cause urinary tract infections,
wound infections, bacteraemia, and infective endocarditis.
Resistant enterococci are selected both in humans and in
animals, owing to the use of antimicrobial agents in both
settings.
In this review, enterococci of animal origin and their
significance for public health are described. This includes
the findings of vancomycin-resistant enterococci and strep-
togramin-resistant E. faecium outside of hospitals, a descrip-
tion of the persistence of vancomycin-resistant enterococci
after the banning of avoparcin, comparison of enterococci
of human and animal origin, and different models with which
to study gene transfer between enterococci of different
origin.
Clinical Background
Over the past two decades, E. faecalis and E. faecium have
become increasingly important pathogens worldwide, espe-
cially because of life-threatening hospital-acquired infections,
including bacteraemia and infective endocarditis [1]. Entero-
coccal bacteraemia is associated with high 30-day mortality
rates.
Enterococci are intrinsically resistant to a number of first-
line antimicrobial agents; they show low-level resistance to
b-lactams, resistance to cephalosporins, and low-level resis-
tance to aminoglycosides. Therefore, treatment of entero-
coccal infections may be difficult. Furthermore, enterococci
can acquire resistance to other antimicrobial agents, including
quinolones, macrolides, tetracyclines, streptogramins, and
glycopeptides [1,2]. Most often, enterococcal infection has
been treated with synergistic and bactericidal therapy with a
combination of an aminoglycoside (gentamicin) and a b-lac-
tam (or other cell wall agents, such as vancomycin). This will
work as long as the organism does not exhibit high-level
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resistance to the aminoglycoside, or resistance to b-lactams
or to vancomycin, making this combination the standard of
care for severe enterococcal infections [3]. Newer antibiot-
ics such as linezolid, daptomycin and tigecycline have good
in vitro activity against enterococcal isolates, although their
clinical use may be limited in certain clinical scenarios as a
result of reduced rates of success, possible underdosing for
enterococci, and low serum levels, respectively, and also by
the emergence of resistance [3]. E. faecium is among the so-
called ‘ESKAPE’ pathogens (E. faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas
aeruginosa, and Enterobacter species), which cause the major-
ity of the infections in US hospitals and effectively ‘escape’
the effect of antibacterial drugs [4].
First Reports on Vancomycin-resistant
Enterococci and Quinupristin–dalfopristin-
resistant E. faecium Outside Hospitals
The first description of a non-human reservoir of vancomy-
cin-resistant E. faecium was published in 1993 [5]. Bates et al.
detected vancomycin-resistant E. faecium in farm animals in
the UK, even though vancomycin never had been used for
the treatment of animals. However, another glycopeptide,
avoparcin, had, since the mid-1970s, been approved as an
additive in feed for farm animals in many countries (although
not in the USA and Canada). It was hypothesized that avo-
parcin was selecting for vancomycin-resistant enterococci in
animals.
This hypothesis was tested with aimed studies in poultry
flocks and pig herds fed with feed with or without avoparcin.
These studies confirmed that avoparcin in the feed had a sig-
nificant role in selecting for vancomycin-resistant E. faecium
in the animals [6,7].
After the first paper from Bates et al., several papers
from many parts of the world described vancomycin-resis-
tant enterococci from many different non-human sources,
e.g. cats, dogs, horses, wild birds, foxes, wood frogs,
ostriches, pigs, pork, broilers, poultry meat, environmental
samples, and sewage, as well as from stool samples from
farmers and non-hospitalized humans in the community.
Most of the studies reported isolation of vancomycin-resis-
tant E. faecium from the community, whereas only a limited
number of studies detected vancomycin-resistant E. faecalis
from non-hospital sources. In the mid-1990s, vancomycin
was one of only a few antimicrobial agents remaining for
the treatment of ampicillin-resistant and gentamicin-resis-
tant E. faecium isolates causing life-threatening infections
(e.g. bacteraemia and infective endocarditis), which were
already common. It was therefore of major concern that
large amounts of avoparcin were used as feed additives for
animal production, thereby selecting for vancomycin-resis-
tant enterococci. In 1994, 24 kg of active vancomycin was
used for human therapy in Denmark, whereas 24 tons of
avoparcin was used for pig and broiler production [8].
From 1992 to 1996, Australia imported an average of
582 kg of vancomycin per year for human medical pur-
poses, and 62.6 tons of avoparcin per year for animal pro-
duction [9].
In 1997, Woodford et al. [10] reported the finding of
quinupristin–dalfopristin-resistant E. faecium in non-hospital-
ized humans in the UK. Quinupristin–dalfopristin and other
streptogramins used for human therapy were not licensed in
the UK at that time for use in humans. The finding of quinu-
pristin–dalfopristin-resistant E. faecium isolates outside hospi-
tals was assumed to be associated with the use of
virginiamycin for animals [11–13]. The vat(D) and vat(E)
genes, encoding streptogramin A resistance in E. faecium,
have been detected in E. faecium isolates from poultry, pigs,
pork, sewage and animal manure in Europe, Asia and the
USA. Recently, two new streptogramin A resistance genes,
vga(D) and vat(H), have been detected in E. faecium isolates
from healthy humans, pigs, poultry and chicken meat in
Korea [14].
On the basis of the precautionary principle, regarding con-
cerns about human health, the use of avoparcin was banned
in Denmark and Norway in 1995, in Germany in 1996, and
in the rest of the EU in 1997. Avoparcin was banned in
Korea in 1997, and in Taiwan and New Zealand in 2000
[15–17]. Like avoparcin, virginiamycin was banned in Den-
mark in 1998 and in all of the EU in 1999 on the precaution-
ary principle. In Australia, its use was restricted to
therapeutic purposes in 2008.
The use of antimicrobial agents for growth promo-
tion was banned in all EU countries in 2006, but antimi-
crobial agents are still used for the treatment of animals.
Tetracycline, in particular, is used to a great extent in
animal production. Even though tetracycline is not used
for the treatment of enterococcal infections in humans, it
is important for the selection of resistant enterococci, as
tetracycline-resistant enterococci are often resistant
to other antimicrobial agents (e.g. vancomycin and genta-
micin).
Like tetracycline, tylosin (a macrolide) is used for the
treatment of diseases in pigs. The erm(B) gene encodes
resistance to both tylosin and erythromycin. The use of tylo-
sin might be related to the persistence of vancomycin-
resistant enterococci in pigs; this is described in detail below
[18].
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Persistence of Vancomycin-resistant
E. faecium After the Banning of Avoparcin
Several studies from countries around the world (e.g.
Denmark, Norway, Portugal, Taiwan, Korea, and New
Zealand) have shown that vancomycin-resistant E. faecium
persisted in animals for an extended time after the ban-
ning of avoparcin. Vancomycin-resistant E. faecium isolates
with indistinguishable or highly similar pulsed-field gel elec-
trophoresis (PFGE) profiles were obtained from consecu-
tive broiler flocks reared in the same house, and from
environmental samples obtained in the houses in between
the flocks. In contrast, isolates from different broiler
houses and from flocks reared in different houses
appeared to be genetically unrelated. These findings indi-
cated that vancomycin-resistant E. faecium isolates were
transmitted between consecutive broiler flocks by clones
of resistant bacteria surviving in the broiler houses despite
cleaning and disinfection between production cycles [19].
The same clones of vancomycin-resistant E. faecium were
detected in Danish pigs and in healthy humans [18,20].
Thirteen years after the banning of avoparcin, the same
clones could be detected in pigs (A. M. Hammerum,
unpublished data).
One of the explanations for the persistence of vanco-
mycin-resistant E. faecium is co-selection with other antimi-
crobial agents or metals. In the Danish pig industry,
vancomycin-resistant E. faecium persisted in faeces from
pigs at a frequency of approximately 20% until the use of
tylosin was reduced; thereafter, the occurrence of vanco-
mycin-resistant E. faecium decreased to only a few per cent
[18]. The persistence could be explained by co-selection
with tylosin, as erm(B) and vanA were located on the same
plasmid [18]. Likewise, copper sulphate (used as a growth-
promoting feed supplement for pigs) was selecting for
vancomycin-resistant E. faecium, as the copper resistance
gene tcrB was found on a plasmid containing both vanA
and erm(B) [21]. Furthermore, many of the vancomycin-
resistant E. faecium isolates are also resistant to tetracy-
cline, which is also used for animal production. Tetracy-
cline might therefore co-select for vancomycin-resistant
E. faecium as well.
Johnson et al. have recently used Danish surveillance
data in a mathematical model for the persistence of vanco-
mycin-resistant E. faecium in the Danish broiler industry.
These analyses suggested that acquired vancomycin resis-
tance would persist for more than 25 years—until 2036
[22].
Comparison of Enterococcal Isolates of
Animal Origin with Enterococcal Isolates of
Human Origin
Since the detection of vancomycin-resistant enterococci and
streptogramin-resistant E. faecium outside hospitals, different
molecular typing methods have been used to compare
enterococci obtained from different sources. In some stud-
ies, genetic profiles were compared to investigate clonal
transfer between enterococci. This is described below, as
are other studies that compared the vanA transposon from
different reservoirs.
In the first typing studies, PFGE was used for comparison
of E. faecium isolates of animal origin with E. faecium isolates
of human origin. Similar and highly similar PFGE profiles
were found for vancomycin-resistant animal isolates and
human stool isolates, respectively [20,23].
Later, amplified fragment length polymorphism analysis and
multilocus sequence typing (MLST) were used for comparison
of E. faecium isolates of different origin. The first amplified
fragment length polymorphism study led to the conclusion
that vancomycin-resistant E. faecium strains were predomi-
nantly host-specific, and strains isolated from hospitalized
patients were genetically different from the prevailing vanco-
mycin-resistant E. faecium strains present in the faecal flora of
non-hospitalized humans [24]. The first MLST studies showed
that outbreak isolates from hospitalized humans clustered in
a subgroup, clonal complex (CC)17, whereas E. faecium iso-
lates of animal origin belonged to other sequence types (STs)
and CCs [25,26]. The CC17 E. faecium isolates have been
found in at least five continents; they most often show ampi-
cillin resistance and high-level ciprofloxacin resistance, and
many show vancomycin resistance and carry specific virulence
genes [24,27]. E. faecium isolates were therefore thought to
be host-specific. Later studies have shown that dogs can be a
reservoir of E. faecium isolates belonging to STs related to
isolates from clinical infections or hospital outbreaks with
ST17 as the primary founder [28,29]. However, it is impor-
tant to note that the dogs in the study by Ghosh et al. [29]
had all been at a veterinary intensive-care unit, and so might
have differed from the normal healthy dog population. A few
other studies have detected E. faecium isolates of animal ori-
gin belonging to CC17: ST132 (part of CC17) isolates were
obtained from a pig and from a human urinary tract infection
[30]; a vanB2 ST17 E. faecium isolate was obtained from
chicken meat and an E. faecium isolate was obtained from veal
in a Spanish study [31]; and a vanA ST78 E. faecium isolate
was obtained from rabbit meat [31].
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E. faecium isolates from pigs most often belong to a single
cluster (CC5) by MLST. vanA E. faecium isolates belonging to
CC5 have been found in pigs from five European countries
and the USA [30]. Furthermore, CC5 E. faecium isolates
have also been found in patients with urinary tract infections
and in faecal samples from non-hospitalized humans [30].
More recently, E. faecalis isolates from different sources
have been compared; as for E. faecium, E. faecalis outbreaks
in hospitals have been related to specific MLST clonal com-
plexes (CC2, CC9, and CC87). CC2 (ST6) has also been
detected outside hospitals in pigs and in healthy infants
[32,33]. Other STs seem to be more widespread; for exam-
ple, ST16 E. faecalis isolates have been detected in pigs, poul-
try, healthy humans, and patients [32–35]. Furthermore,
E. faecalis isolates with high-level resistance to gentamicin
belonging to ST16, and with similar PFGE types, have been
obtained from pigs, pork, non-hospitalized humans, and
patients with endocarditis [36]. ST116 was found in vanA
E. faecalis isolates from turkey meat, non-hospitalized
humans, and a patient [37]. E. faecalis isolates of ST40 and
ST97 have been detected in both pigs and endocarditis
patients [38].
The vanA gene is located on a 10 851-bp transposon,
named Tn1546. It encodes nine polypeptides that can be
assigned to various functional groups: transposition (ORF1
and ORF2), regulation of resistance gene expression (VanR
and VanS), synthesis of the D-Ala-D-Lac depsipeptide (VanH
and VanA), and hydrolysis of peptidoglycan precursors (VanX
and VanY). The function of VanZ remains unknown. Several
groups have characterized and compared Tn1546 transpo-
sons from different sources to investigate the possible hori-
zontal transfer of vanA between enterococci of animal origin
and enterococci of human origin.
Even though Tn1546 transposons in most of the studied
enterococci were heterogeneous, several groups detected
the same variant of Tn1546 in enterococci of human and
non-human origin [39–42]. Furthermore, Jensen found a
point mutation in vanX (G to T) at position 8234 in Tn1546.
The variant with a T was associated with a pig origin of the
vancomycin-resistant E. faecium isolates, whereas a G in
position 8234 was detected in isolates of poultry origin.
Both types were found among human E. faecium isolates
[39,43].
In conclusion, E. faecium isolates from clinical outbreaks
most often belong to different types than E. faecium from
animals, food, and humans in the community. Even though
E. faecalis isolates from hospital outbreaks also belong to
specific types, the same MLST types can be detected in
E. faecalis isolates from animals, meat, faecal samples from
humans in the community, and patients with bloodstream
infections. The same variants of Tn1546 can be detected
in enterococci of both human and animal origin. This
indicates the possibility of horizontal transfer of
Tn1546 between enterococci occupying various ecological
niches.
Can vanA be Transferred Between
Enterococci of Animal and Human Origin
in the Intestine?
The intestines of animals, including humans, are ideal places
for gene transfer, and several models have been used to
study gene transfer between enterococci in the intestine.
These models include gnotobiotic mice/rats and gnotobiotic
mice with a human microbiota; gene transfer has also been
studied in the intestines of healthy humans.
Two different studies showed transfer at a high frequency
of vanA from an E. faecium isolate of animal origin to an
E. faecium isolate of human origin in the intestine of gnoto-
biotic mice [44,45]. Mater et al. and Bourgeois-Nicolaos
et al. observed transfer of vanA from an E. faecium donor to
an E. faecium recipient in the intestines of gnotobiotic mice
with human faecal flora [46]. Transfer of vanA from an
E. faecium isolate of animal origin to an E. faecium isolate of
human origin has also been investigated in the intestines of
healthy human volunteers. In vivo conjugation occurred in
three of six volunteers [47]. In one volunteer, co-transfer
of several resistance genes occurred. The vanA gene was
transferred together with vat(E) and erm(B) (encoding strep-
togramin and macrolide resistance, respectively). The recipi-
ent strain in the above-mentioned study by Lester and
Hammerum [48] did not belong to CC17. In a recent study,
vanA of animal origin was transferred to a CC17 recipient
(obtained from a patient with sepsis) in the intestines of
cephalosporin-treated mice. This study shows that, even
though vanA CC17 E. faecium isolates are associated with
hospital outbreaks, the vanA genes in these isolates could
have an animal origin.
Lim et al. [49] found very similar plasmids from humans
and chickens, indicating gene transfer between different
hosts. Furthermore, Sletvold et al. compared a vanA E. fae-
cium plasmid from a farmer with a vanA E. faecium plasmid
from his poultry. The two plasmids shared 43 coding
sequences, and the only nucleotide difference was an 88-bp
indel [50].
Most Tn1546 transposons are plasmid-borne. The studies
described above illustrate that horizontal transfer of vanA
(Tn1546) between enterococci of different origin can occur
in the intestine.
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Are Enterococci of Animal Origin a Human
Hazard?
Transient colonization with enterococci of animal origin has
been shown in the intestines of healthy humans not receiving
antimicrobial agents for between 4 to 30 days [51,52]. These
resistant enterococci may act as donors of resistance genes
(e.g. vanA and vat(E)). Lester and Hammerum showed this
transfer to CC17 E. faecium in the intestines of cephalospo-
rin-treated mice, whereas, in the study by Lester et al., gene
transfer in the intestines of healthy humans was investigated
without antimicrobial treatment, because of ethical consider-
ations. Gene transfer of vanA may occur in the intestines of
human patients, from an E. faecium strain of animal origin
(obtained prior to the hospital stay or from eating meat con-
taining resistant E. faecium strains during the stay) to a hospi-
tal CC17 E. faecium strain obtained during the hospital stay.
One of the major risk factors in relation to colonization or/
and infection with enterococci is antimicrobial treatment.
Ubeda et al. [53] have shown, by 16S DNA pyrosequencing,
that antimicrobial treatment can disrupt the microbiota,
enabling vancomycin-resistant enterococci to undergo dra-
matic expansion and thereafter dominate the microbial popu-
lation of the ileum and caecum. In the clinical setting, Ubeda
et al. [53] found that intestinal domination by vancomycin-
resistant enterococci preceded bloodstream infections in
patients undergoing allogeneic haematopoietic stem cell
transplantation. In conclusion, E. faecium strains of animal
origin most often do not constitute a human hazard in them-
selves, but they can act as donors of antimicrobial resistance
genes for other pathogenic enterococci.
The situation seems to be different for E. faecalis of animal
origin. Larsen et al. [36,38] found E. faecalis isolates from
human patients and pigs with highly similar profiles in rela-
tion to resistant pattern, virulence gene profile, and MLST/
PFGE types. This indicates that E. faecalis from pigs might
constitute a human hazard.
It is hard to quantify this risk for both E. faecium and
E. faecalis of animal origin in relation to human health, and
further studies are needed.
Further Perspectives
Enterococci can survive and live in harsh environments, and
are therefore hard to eradicate in both animal production and
clinical settings. Proper cleaning of animal production facilities,
such as according to the ‘all-in/all-out principle’ (working in
the poultry houses), can minimize the persistence of entero-
cocci in poultry houses. In slaughterhouses, good hygiene is
also essential to minimize faecal contamination of the meat
with enterococci and other zoonotic bacteria. Similarly, good
hand hygiene and proper cleaning is crucial in the clinical set-
ting to avoid nosocomial infections with enterococci.
Even though the use of growth promoters is banned in all
EU countries, avoparcin and virginiamycin are still used in
other parts of the world. Furthermore, other antimicrobial
agents used in animal production for therapy can select for
vancomycin-resistant enterococci, owing to co-resistance.
Prudent use of antimicrobial agents in animal production is
therefore essential to lower the risk of selection of resistant
enterococci or other bacteria with a zoonotic potential
(methicillin-resistant S. aureus, resistant Escherichia coli, and
resistant Salmonella species). In the human clinical setting,
prudent use of antimicrobial agents is also needed to
decrease the number of nosocomial enterococcal infections,
as antimicrobial agents constitute a risk factor for infections
with enterococci.
Antimicrobial resistance can easily be transferred between
borders, because people travel, and meat and livestock are
exported. Antibiotic resistance is therefore not only a national
problem, but also a global problem. A global policy on the pru-
dent use of antimicrobial agents for both human and animal
infections is therefore required to avoid the spread of resis-
tance; the use of antimicrobial agents for growth promotion
should be stopped in all countries around the world.
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